Catalent Completes Acquisition of MaSTherCell

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics. With the addition of MaSTherCell’s unique portfolio of capabilities, technologies, and related analytical services spanning both autologous and allogeneic cell therapies, Catalent is well positioned to lead the industry with its cell & gene therapy platforms.

Read the full article: Catalent Completes Acquisition of MaSTherCell //


Scroll to Top